The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome
- 7 April 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 72 (14) , 1242-1247
- https://doi.org/10.1212/01.wnl.0000345664.72220.6a
Abstract
Background: Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2). Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor playing a major role in neuronal survival, neurogenesis, and plasticity, and it has been shown that BDNF expression is regulated by MeCP2 through a complex interaction. A common polymorphism of BDNF (Val66Met [p.V66M]) has been found to correlate with severity and course of several neuropsychiatric disorders. Methods: We examined the association between disease severity score, assessed by the modified Percy score, and BDNF polymorphism, using regression methods, in 125 mutation-positive patients with RTT from the Australian Rett Syndrome Database and an Israeli cohort. Results: Those who were heterozygous (Val/Met) had slightly more severe disease than those who were homozygous for the wild-type (Val/Val) BDNF polymorphism (increased severity score 2.1, p = 0.09). In those with p.R168X, a commonly occurring MECP2 mutation in RTT, there was a 6-point increase in severity score for those who were heterozygous for the BDNF polymorphism, both unadjusted (p = 0.02) and adjusted for age (p = 0.03). Individuals with the p.R168X mutation and heterozygous for the BDNF polymorphism were also at an increased risk of seizure onset (hazard ratio 5.3, 95% confidence interval 1.6–17.7) compared with those homozygous for the wild-type BDNF allele. Conclusions: In addition to mutation type and degree of X-chromosome skewing, the common brain-derived neurotrophic factor (BDNF) polymorphism appears to be another genetic modifier of Rett syndrome (RTT) severity. This suggests that BDNF function may play a significant role in the pathogenesis of RTT. ARSD = Australian Rett Syndrome Database; BDNF = brain-derived neurotrophic factor; CI = confidence interval; HR = hazard ratios; MECP2 = methyl CpG-binding protein 2; Met = methionine; NAA = N-acetylaspartate; RTT = Rett syndrome; Val = valine.This publication has 41 references indexed in Scilit:
- MeCP2, a Key Contributor to Neurological Disease, Activates and Represses TranscriptionScience, 2008
- BDNF Val66Met variant and age of onset in schizophreniaAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2008
- Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndromeNeurology, 2008
- Association Between Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism and Progressive Brain Volume Changes in SchizophreniaAmerican Journal of Psychiatry, 2007
- Seizures in Rett syndrome: An overview from a one-year calendar studyEuropean Journal of Paediatric Neurology, 2007
- Temporal grey matter reductions in bipolar disorder are associated with the BDNF Val66Met polymorphismMolecular Psychiatry, 2007
- The diagnosis of autism in a female: could it be Rett syndrome?European Journal of Pediatrics, 2007
- Predictors of seizure onset in Rett syndromeThe Journal of Pediatrics, 2006
- Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivationJournal of Medical Genetics, 2006
- Describing the phenotype in Rett syndrome using a population databaseArchives of Disease in Childhood, 2003